Twist Bioscience Stock: 7 Straight Green Days, Up 33%
A sustained rally has pushed the biotech stock higher for seven straight days, raising questions about the business fundamentals supporting its new price.
Twist Bioscience (TWST) stock has gained 33% over seven consecutive trading days. That streak has added about $2.6 billion to the company’s market value, which now stands at over $10 billion.
For anyone holding the stock, this run has been a significant event. The move has occurred while the S&P 500 returned just +0.2% over the same 7 trading days, making this rally the stock’s own story.
The streak next to the S&P 500
Here is how TWST stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | TWST | S&P 500 |
|---|---|---|
| 1D | 7.3% | 0.2% |
| 7D (Current Streak) | 33.0% | 0.2% |
| 1M (21D) | 17.3% | -0.7% |
| 3M (63D) | 90.7% | 2.0% |
| YTD 2026 | 426.5% | 11.8% |
| 2025 | -31.7% | 16.4% |
| 2024 | 26.1% | 23.3% |
| 2023 | 54.8% | 24.2% |
What do the fundamentals say about this price?
The evidence on the underlying business is mixed. Revenue over the last twelve months grew 19.2%, which is ahead of the 8.1% median for S&P 500 Health Care stocks.
On the other hand, the company’s operating margin over the last twelve months is -32.0%, compared to a median of 17.6% among S&P 500 Health Care stocks. Twist Bioscience also has negative trailing earnings and its stock trades at about $166.99 a share as of 9/18/2026.
A streak is information, not an instruction.
A multi-day run like this one is a clear signal of momentum and heightened investor attention. It is not, by itself, a reason to buy or sell. The disciplined response is to treat the new price as a prompt to re-examine the business. The fundamental picture, with its competing signals on growth and profitability, provides a starting point for that work.
If you are hunting for strength that has more behind it than a hot tape, our Guidance Momentum screen surfaces the names where management raised its own outlook, which is the kind of momentum that tends to persist.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the whole group, not the single stock. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
One hot stock is a story. Thirty sound ones are a strategy
A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?
The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Follow the story; invest in the strategy.